ADC Therapeutics SA (ADCT) vs Cue Biopharma (CUE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cue Biopharma (CUE) has outperformed ADC Therapeutics SA (ADCT) over the past year, losing 13.2% versus a loss of 62.3%. Over five years, ADCT leads with a -93.2% price change compared with -94.1% for CUE. ADC Therapeutics SA is the larger company by market cap ($220.9 million vs $200.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | CUE |
|---|---|---|
| Share price | $1.73 | $27.66 |
| Market cap | $220.87M | $200.93M |
| 1-day change | +8.81% | +23.87% |
| YTD return | -50.99% | +144.04% |
| 1-year return | -62.31% | -13.25% |
| 5-year return | -93.21% | -94.09% |
| EPS (TTM) | $-0.60 | $-29.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.98 | $45.50 |
| 52-week low | $0.78 | $4.98 |
| Distance from 52-week high | -65.26% | -39.21% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +92.49% | +218.15% |
| Average volume | 1.43M | 267.15K |
| Shares outstanding | 127.67M | 7.26M |
| Employees | 188 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CUE has outperformed ADCT by 49.1 percentage points over the past year.
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
ADCT vs CUE FAQ
Which is bigger, ADC Therapeutics SA or Cue Biopharma?
ADC Therapeutics SA (ADCT) is larger, with a market capitalization of $220.87M compared with $200.93M for Cue Biopharma (CUE).
Which stock has performed better over the past year, ADCT or CUE?
CUE returned -13.25% over the past 12 months, compared with -62.31% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Are ADC Therapeutics SA and Cue Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.